Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride

AIMS/INTRODUCTION: Dipeptidyl peptidase‐4 inhibitors might have pleiotropic protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas. Therefore, we compared various CVD risk factors between vildagliptin and glimepiride. MATERIALS AND METHODS: We carried out a randomized, prospective and crossover trial. A total of 16 patients with type 2 diabetes whose glycated hemoglobin was >7% were randomized to add vildagliptin or glimepiride. After 12‐week treatment, each drug was replaced with the other for another 12 weeks. Before and after each treatment, glucose homeostasis and CVD risk factors were assessed, and the continuous glucose monitoring system was applied to calculate glycemic variability. RESULTS: The mean age of the participants was 60 years, 31% were men, body mass index 25.5 kg/m(2) and HbA1c 8.41%. Both vildagliptin and glimepiride significantly decreased glycated hemoglobin and glycemic variability indices. Despite the improved glucose homeostasis, favorable change of CVD markers was not prominent in both the arms, along with significant weight gain. Only plasma stromal cell‐derived factor (SDF)‐1α decreased by 30% in the vildagliptin arm. According to regression analyses, the reduction of SDF‐1α was independently associated with vildagliptin usage and serum interleukin‐6 changes, but white blood cells were not related with the SDF‐1α changes. CONCLUSION: Compared with glimepiride, vildagliptin arrestingly decreased plasma SDF‐1α, and its clinical implications should be further investigated.